Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel

Endoscopy

Volumn 32, Issue 3, 2000, Pages 245-254

  Reinacher Schick, A ^a   Seidensticker, F ^a   Petrasch, S ^a   Reiser, M ^a   Philippou, S ^b   Theegarten, D ^b   Freitag, G ^b   Schmiegel, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; MONOCLONAL ANTIBODY KI 67; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; COLON POLYP; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL DIVISION; CHEMOPREVENTION; FEMALE; HUMANS; INTESTINAL MUCOSA; INTESTINAL POLYPS; MALE; MESALAMINE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0033950737     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-135     Document Type: Article

References (62)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics. 1996. CA Cancer J Clin 1996; 46: 5-27
2. Kune G, Kune S, Watson L. Colorectal cancer risk, chronic illnesses, operations, and medications: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-4404
3. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596
4. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-614
5. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159: 161-166
6. Rosenberg L. Louik C, Shapiro S. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998; 82: 2326-2333
7. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710-714
8. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-1472
9. Ritland SR, Gendler SJ. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis 1999; 20: 51-58
10. Mahmoud NN, Dannenberg AJ, Mestre J, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998; 124: 225-231
11. Labayle D, Fischer D, Vielh P. et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639
12. Giardello FM, Hamilton SR, Krush AJ, et al. Treatment of coIonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316
13. Matsuhashi N, Nakajima A, Fukushima Y, et al. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997; 40: 344-349
14. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-1016
15. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative metaanalysis. BMJ 1996; 312: 1563-1566
16. Bjarnasson I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-1847
17. Shmueli E, Record CO. Adverse effects of the aminosalicylates. Adverse Drug Reaction Bulletin 1994; 165: 623-626
18. Brimblecombe R. Mesalazine. A global safety evaluation. Scand J Gastroenterol 1990; 25 (Suppl. 172): 66-68
19. Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989; 97: 38-41
20. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117-120
21. Moody GA, Jayanthi V, Probert CSJ, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-1183
22. Eaden JA, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Gastroenterology 1999; 116(Suppl.): G1739
23. MacGregor DJ, Kim YS, Siddiki BB, et al. Induction of colon cancer cell apoptosis in vitro and inhibition of intestinal tumor formation in Min/+mice by balsalazide and metabolites. Gastroenterology 1996; 110 (Suppl.): A553
24. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Topical administration of 5-ASA results in increased apoptosis of colorectal cancer. Gastroenterology 1999; 116 (Suppl.): G1680
25. MacGregor DJ, Kim YS, Sleisenger ME, Johnson LK. Inhibition of colon cancer cell proliferation in vitro and azoxymethane-induced aberrant crypt formation in vivo by balsalazide and metabolites. Gastroenterology 1995; 108 (Suppl.): A500
26. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-5589
27. Smith BJ, Curtis JF. Eling TE. Bioactivation of xenobiotics by prostaglandin H synthetase. Chem Biol Interact 1991; 79: 245-264
28. Tsujii M, Kawano S, Tsujii S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716
29. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789
30. Eberhart CE, Coffey RJ, Radhika A. et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188
31. Partik G, Kahl-Rainer P, Sedivy R, et al. Apoptosis in human colorectal tumours: ultrastructure and quantitative studies on tissue localization and association with bak expression. Virchows Arch 1998; 432: 415-426
32. Tsujitani S, Shirai H, Tatebe S, et al. Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma. Cancer 1996; 77: 1711-1716
33. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55: 1811-1816
34. Moss SF, Scholes JV, Holt PR. Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxyuridine nick end labeling. Dig Dis Sci 1996; 41: 2238-2247
35. Langman M, Boyle P. Chemoprevention of colorectal cancer. Gut 1998; 43: 578-585
36. Qiao L, Hanif R, Sphicas E, et al. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol 1998; 55: 53-64
37. Piazza GA, Rahm ALK, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3110-3116
38. Elder DJE, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996; 56: 2273-2276
39. Giardina C, Boulares H, Inan MS. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. Biochim Biophys Acta 1999; 1448: 425-438
40. Erickson BA, Longo WE, Panesar N, et al. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 1999; 81: 101-107
41. Picariello L, Brandi ML, Formigli L, et al. Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms. Eur J Pharmacol 1998; 360: 105-112
42. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-998
43. Winde G, Schmid KW, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 1995; 38: 813-830
44. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer 1986; 38: 173-176
45. O'Brien MJ, Winawer SJ, Zauber AG, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98: 371-379
46. Neugut AI, Jacobson JS, Ahsan H, et al. Incidence and recurrence rates of colorectal adenomas: a prospective study. Gastroenterology 1995; 108: 402-408
47. Van Stolk RU, Beck GJ, Baron JA, et al, for the Polyp Prevention Study Group. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. Gastroenterology 1998; 115: 13-18
48. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501
49. Sträter J, Koretz K, Gunthert AR, Möller P. In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis. Gut 1995; 37: 819-825
50. Frisch SM, Francis H. Disruption of epithelial cell-matrix interaction induces apoptosis. J Cell Biol 1994; 124: 619-626
51. Liu LU, Holt PR. Krivosheyev V, Moss SF Human right and left colon differ in epithelial cell apoptosis and in the expression of bak, a pro-apoptotic Bcl-2 homologue. Gut 1999; 45: 45-50
52. Anti M, lascone E, Morini S, et al. Apoptosis and cell proliferation along the entire colonie mucosa in subjects at risk for colorectal cancer. Gastroenterology 1997; 112 (Suppl.): A533
53. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362-366
54. Bostick RM, Fosdick L, Wood JR, et al. Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: a randomized, double-blinded, placebo-controlled clinical trial. J Natl Cancer Inst 1995; 87: 1307-1315
55. Goldberg Y, Nassif II, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alteration in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996; 12: 893-901
56. Lee FD. Importance of apoptosis in the histopathology of drug related lesions of the large intestine. J Clin Pathol 1993; 46: 118-122
57. Keller JJ, Offerhaus GJA, Goodman SN, et al. Change in apoptosis in patients treated with sulindac. Gastroenterology 1998; 114 (Suppl.): G2550
58. Sandoval M, Liu X, Mannick EE, et al. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Gastroenterology 1997; 113: 1480-1488
59. Shiff SJ, Qioa L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491-503
60. Yang F, de Villiers WJS, McClain CJ, Varilek GW. Mesalamine modulates nuclear factor-kB/IkB-alpha in Caco-2 cells. Gastroenterology 1997; 112 (Suppl.): A1125
61. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999; 116: 602-609
62. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappaB. J Clin Invest 1998; 101: 1163-1174